{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:27:50Z","timestamp":1793744870837,"version":"4.6.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102230","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:09:49Z","timestamp":1791475789000},"page":"102230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Folate receptor alpha expression in uterine serous carcinoma: a single-institution analysis"],"prefix":"10.1016","volume":"67","author":[{"given":"Sadhvi","family":"Batra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Skala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bori","family":"Lesser-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitanshu","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Ni","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102230_bb0005","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic oncology group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102230_bb0010","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1535-7163.MCT-17-0930","article-title":"In vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers","volume":"17","author":"Altwerger","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.gore.2026.102230_bb0015","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102230_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102779","article-title":"Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models","volume":"36","author":"Ettorre","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102230_bb0025","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102230_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/PGP.0000000000001208","article-title":"Folate receptor alpha (FR\u03b1\/FOLR1) immunohistochemical expression across molecularly classified endometrial carcinomas","author":"Libert","year":"2026","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.gore.2026.102230_bb0035","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102230_bb0040","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102230_bb0045","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1038\/s41467-026-71102-x","article-title":"Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial","volume":"17","author":"Porter","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gore.2026.102230_bb0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2024.11.010","article-title":"Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers","volume":"192","author":"Previs","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102230_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102879","article-title":"Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: a retrospective real-world analysis","volume":"36","author":"Roberts","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102230_bb0060","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/sj.bjc.6601791","article-title":"Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling","volume":"90","author":"Santin","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gore.2026.102230_bb0065","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases","volume":"91","author":"Slomovitz","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102230_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70087","article-title":"Folate receptor alpha (FR\u03b1) expression in tubo-ovarian and endometrial tumors: a study of 923 cases","volume":"12","author":"Toltesi","year":"2026","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.gore.2026.102230_bb0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2025.05.001","article-title":"FR\u03b1 expression in advanced endometrial carcinoma: clinicopathological, molecular, and prognosis correlates","volume":"197","author":"Xiao","year":"2025","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926002109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926002109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:00:51Z","timestamp":1793743251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926002109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S2352578926002109"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102230","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folate receptor alpha expression in uterine serous carcinoma: a single-institution analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102230"}}